Table A2.
Baseline socio-demographic and health characteristics for each group at cluster level.
| Characteristic | Usual care | Eligible patients (ITT) | Patients with counseling (PP) | Overall |
|---|---|---|---|---|
| GENDER (NO/CLUSTER) | ||||
| Female | 38.2 (34.3) | 34.3 (41.2) | 12.6 (17.6) | 72.5 (85.7) |
| Male | 31.7 (44.1) | 25.2 (30.6) | 8.0 (10.0) | 56.9 (64.0) |
| PHARMACY INCLUSION PHASE | ||||
| Phase 1 | 113.9 (102.5) | 95.2 (76.3) | 33.4 (29.8) | 209.2 (158.3) |
| Phase 2 | 14.5 (14.4) | 14.4 (13.7) | 3.8 (2.8) | 28.9 (24.4) |
| AGE GROUPS (NO/CLUSTER) | ||||
| 18–50 | 19.7 (22.5) | 20.3 (28.2) | 6.4 (11.5) | 40.0 (49.3) |
| 51–65 | 25.8 (37.4) | 19.8 (25.4) | 6.6 (8.6) | 45.6 (52.1) |
| >65 | 24.5 (35.5) | 19.4 (26.9) | 7.6 (11.5) | 43.8 (51.4) |
| NUMBER OF PATIENTS STARTING | ||||
| Overall | 69.9 (91.2) | 59.5 (70.1) | 20.7 (26.8) | 129.4 (149.0) |
| RAS-inhibitors | 25.3 (48.1) | 16.3 (31.0) | 9.5 (10.7) | 41.7 (49.3) |
| Statins | 25.9 (48.7) | 16.1 (33.5) | 9.9 (14.0) | 42.0 (51.4) |
| Bisphosphonates | 4.8 (8.1) | 6.1 (11.4) | 5.7 (8.2) | 11.0 (11.6) |
| Antidepressants | 13.9 (23.3) | 20.9 (40.5) | 16.3 (23.4) | 34.8 (39.9) |
| CHRONIC DISEASE SCORE | ||||
| 0–1 | 27.3 (33.0) | 24.8 (29.1) | 7.9 (11.5) | 52.0 (59.9) |
| 2–4 | 27.3 (33.0) | 16.9 (22.7) | 5.8 (8.3) | 38.4 (43.8) |
| 5–19 | 21.2 (29.5) | 16.5 (21.2) | 6.4 (8.0) | 37.7 (45.0) |
| Status score | ||||
| < –1.0 | 24.4 (55.4) | 20.5 (45.1) | 7.7 (18.2) | 44.9 (96.1) |
| –1 to 0.5 | 24.4 (44.3) | 18.0 (29.5) | 6.2 (12.2) | 42.4 (67.6) |
| >0.5 | 21.1 (33.6) | 21.1 (35.0) | 6.7 (10.7) | 42.2 (64.2) |
Values are means per cluster (standard deviation) unless stated otherwise.